AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
A phase 3 trial of Oxaliplatin and Bevacizumab in colorectal cancer, run by Akeso, now recruiting.
Overview
AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer is a phase 3 interventional study registered as NCT06951503 by Akeso, with 560 participants planned, started 2025-05-27 and due to reach its primary completion in 2027-01-13. Interventions recorded: AK112, Oxaliplatin, Irinotecan, Leucovorin and 5-FU and Bevacizumab.
Similar pages
not linked directly; found by shared links- TrialA Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.
Shares Oxaliplatin, Bevacizumab, Colorectal cancer and the tag pipeline.
- TrialStudy of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
Shares Oxaliplatin, Bevacizumab, Colorectal cancer and the tag pipeline.
- TrialA Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Shares Oxaliplatin, Bevacizumab, Colorectal cancer and the tag pipeline.
- TrialA Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
Shares Oxaliplatin, Akeso and the tag pipeline.
- TrialA Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors
Shares Akeso and the tag pipeline.
- TrialA Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors
Shares Akeso and the tag pipeline.
- TrialA Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer
Shares Akeso and the tag pipeline.
- TrialA Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer
Shares Akeso and the tag pipeline.